These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 24122850)

  • 1. What do Canadian uro-oncologists believe patients should know about androgen deprivation therapy?
    Tran S; Walker LM; Wassersug RJ; Matthew AG; McLeod DL; Robinson JW
    J Oncol Pharm Pract; 2014 Jun; 20(3):199-209. PubMed ID: 24122850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patients and partners lack knowledge of androgen deprivation therapy side effects.
    Walker LM; Tran S; Wassersug RJ; Thomas B; Robinson JW
    Urol Oncol; 2013 Oct; 31(7):1098-105. PubMed ID: 22285008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Luteinizing hormone--releasing hormone agonists: a quick reference for prevalence rates of potential adverse effects.
    Walker LM; Tran S; Robinson JW
    Clin Genitourin Cancer; 2013 Dec; 11(4):375-84. PubMed ID: 23891497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and management of osteoporosis in men receiving androgen deprivation therapy: a survey of urologists and radiation oncologists.
    Alibhai SM; Rahman S; Warde PR; Jewett MA; Jaffer T; Cheung AM
    Urology; 2006 Jul; 68(1):126-31. PubMed ID: 16844454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen deprivation therapy: evidence-based management of side effects.
    Ahmadi H; Daneshmand S
    BJU Int; 2013 Apr; 111(4):543-8. PubMed ID: 23351025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New-onset psychosis following androgen deprivation therapy for prostate cancer.
    Bernad DM; Dal Pra A; Baule C; Frey BN; Faria S
    Can J Urol; 2013 Aug; 20(4):6868-70. PubMed ID: 23930615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.
    Conteduca V; Di Lorenzo G; Tartarone A; Aieta M
    Crit Rev Oncol Hematol; 2013 Apr; 86(1):42-51. PubMed ID: 23092636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity.
    Higano CS
    Urology; 2003 Feb; 61(2 Suppl 1):32-8. PubMed ID: 12667885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GU radiation oncologists consensus on bone loss from androgen deprivation.
    Duncan GG; Corbett T; Lukka H; Warde P; Pickles T
    Can J Urol; 2006 Feb; 13(1):2962-6. PubMed ID: 16515750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen deprivation therapy in prostate cancer: anticipated side-effects and their management.
    Kim HS; Freedland SJ
    Curr Opin Support Palliat Care; 2010 Sep; 4(3):147-52. PubMed ID: 20592607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer, osteoporosis and fracture risk.
    Allain TJ
    Gerontology; 2006; 52(2):107-10. PubMed ID: 16508318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
    Harrington JM; Schwenke DC; Epstein DR; Bailey DE
    Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer.
    Freedland SJ; Eastham J; Shore N
    Prostate Cancer Prostatic Dis; 2009; 12(4):333-8. PubMed ID: 19901933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone health management in prostate cancer patients receiving androgen deprivation therapy.
    Dhanapal V; Reeves DJ
    J Oncol Pharm Pract; 2012 Mar; 18(1):84-90. PubMed ID: 21807761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing complications of androgen deprivation therapy for prostate cancer.
    Holzbeierlein JM
    Urol Clin North Am; 2006 May; 33(2):181-90, vi. PubMed ID: 16631456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.